Doramapimod Pembrolizumab WST-8 [2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2

WST-8 [2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2

ZBP1 is highly expressed in lymphatic tissues including lymph node

The profile of extracted protein using traditional methods is usually incomplete

Pexidartinib (PLX-3397) induces cell apoptosis and has anti-tumor activity

Doramapimod Pembrolizumab WST-8 [2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2Doramapimod (BIRB 796) is an orally active, highly potent p38 MAPK inhibitor, which has an IC50 for p38=38 nM, for p38=65 nM, for p38=200 nM, and for p38=520 nM. Doramapimod has picomolar affinity for p38 kinase (Kd=0. 1 nM). Doramapimod also inhibits B Raf with an IC50 of 83 nM.